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Objective: To determine whether technetium Tc 99m ex-
ametazime single-photon computed emission tomography(SPECT) can distinguish gay human immunodeficiency vi-
rus (HIV)\p=m-\positivesubjects, both with and without mild cog-
nitive impairment, from gay HIV-negative control subjects.
Design: Twenty HIV-positive subjects (12 without cog-
nitive impairment and eight with mild cognitive impair-
ment) and 10 HIV-negative subjects underwent neurologi-
cal, neuropsychological, magnetic resonance imaging, and
technetium Tc 99m exametazime SPECT examinations.
Setting: Subjects were recruited from a natural history
study of gay men with HIV infection.
Patients: Subjects from the cohort who had previously
participated in a magnetic resonance imaging study were
selected for the SPECT study.
Main Outcome Measures: The SPECT scans were
rated as abnormal if focal defects, confirmed by a hori-
zontal profile analysis, were seen.
Results: Sixty-seven percent of HIV-positive subjects
without cognitive impairment, 88% of HIV-positive sub-jects with mild cognitive impairment, and 20% of HIV\x=req-\
negative subjects had abnormal SPECT scans (P<.05 for
both HIV-positive groups when each group was com-
pared with HIV-negative subjects).
Conclusion: Compared with gay HIV-negative control
subjects, focal SPECT defects are seen with an increased
frequency in HIV-positive gay men without cognitive im-
pairment and in HIV-positive gay men with mild cogni-
tive impairment.
(Arch Neurol. 1995;52:607-611)
Functional brain imagingusing single-photon emis¬sion computed tomogra¬phy (SPECT) in patientswith both early and
advanced stages of human immunodefi¬
ciency virus (HIV) type 1-associated
dementia complex (ADC) has shown
focal cortical or subcortical perfusion
defects that are associated with a heter¬
ogeneous pattern of cortical uptake.1"9
However, findings from studies of
SPECT in HIV infection are difficult to
interpret because many have included
parenteral drug users as subjects,7'9 and
the perfusion pattern in HIV-negative
subjects with long-term intravenous
drug use cannot be distinguished from
the abnormal SPECT pattern that is
seen in HIV infection.10
The current study was designed to test
the hypothesis that technetium Tc 99m ex-
ametazime SPECT could distinguish HIV-
positive gay men, with or without mild
cognitive impairment, from HIV-
negative gay men.
RESULTS
The subjects are described in Table 1.
Only the CD4 lymphocyte count was sig¬
nificantly different between HIV-
negative subjects and HIV-positive sub¬jects (mean CD4 lymphocyte count
difference, 6.1X107L; P<.01). Twenty-
five percent of the HIV-positive subjects
were medically asymptomatic, 45% had
mild medical symptoms, and 30% had
AIDS-related complex. The CD4 lympho¬
cyte count fell with advancing medical
clinical stage (CD4 lymphocyte count:
medically asymptomatic HIV-positive sub¬jects, 3.6X109/L; HIV-positive subjects
with mild medical symptoms, 3.5 X109/L;
and HIV-positive subjects with AIDS-
related complex, 1.3X109/L).
See Methods on next page
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METHODS
SUBJECTS
Subjects were recruited from a cohort of volunteers from
gay men's organizations. A majority of the subjects were
recruited into the cohort via word of mouth, though two
announcements were placed in gay monthly newsletters and
one in a newspaper.
The following inclusion criteria for the cohort were
used: (1) age between 18 and 60 years, (2) gay or bisexual
men who did not self-administer parenteral drugs more than
10 times since 1982 by self-report, (3) prior knowledge of
HIV status, and (4) fluency in English.
The following exclusion criteria were used: (1) the Cen¬
ters for Disease Control and Prevention National Surveil¬
lance Criteria for acquired immunodeficiency syndrome(AIDS) at the time of enrollment (1988), with the excep¬
tion of AIDS dementia and esophageal candidiasis; (2) pres¬
ence of an encephalopathy that was unrelated to HIV in¬
fection; (3) presence of a chronic neurologic disorder that
antedated HIV infection (eg, Gilles de la Tourette's syn¬
drome); and (4) presence of a major psychiatric disorder
that antedated HIV infection (eg, schizophrenia).
Two hundred seven gay men were enrolled in the co¬
hort, beginning in March 1988, and they were seen every
6 months. From this cohort, 118 men were recruited for a
longitudinal magnetic resonance imaging (MRI) study that
began in September 1989. Thirty-one subjects who par¬
ticipated in the longitudinal MRI study were sequentially
enrolled for the SPECT study, under the following con¬
straints: (1) We attempted to rule out subjects who had a
history of depression, psychosis, or cocaine or crack use
in the psychiatric evaluations prior to the visit in which they
were enrolled. (2) For HIV-positive subjects, we recruited
a small number of subjects who had mild cognitive impair¬
ment in the preceding visit, to serve as a comparison group
for the HIV-positive subjects without cognitive impair-
ment. (3) All subjects volunteered for the study and gave
informed consent. One subject was excluded from the analy¬
sis because he was HIV negative, but he had focal neuro¬
logical signs on physical examination.
The biannual assessments of the cohort have been de¬
scribed in detail elsewhere11·12 and are summarized below.
MEDICAL EVALUATION
Medical evaluation included an examination by a physi¬
cian, a complete blood cell count, and CD4 and CD8 lym¬
phocyte counts. After review of these data, the medical sta¬
tus of each subject was classified as either HIV negative,
HIV positive asymptomatic, HIV positive with mild symp¬




All neurological evaluations were performed by neurolo¬
gists who were blind to HIV serostatus. Subjects under¬
went a structured neurological examination.11 A sum¬
mary score to reflect the overall degree of neurological
disability was calculated based on a modified version of the
Kurtzke Disability Status Scale for Multiple Sclerosis (ie,
the Kurtzke score).11·14 A Kurtzke score of 0 indicated a neu¬
rological examination with normal results, and a score of
1 indicated no disability and minimal signs, such as fron¬
tal release signs or Babinski's sign. A detailed psychiatric
assessment was also performed, without knowledge of the
subject's serostatus.15
NEUROPSYCHOLOGICAL EVALUATION
Neuropsychological testing was performed, blind to the sub¬ject's serostatus, and this testing assessed memory, lan¬
guage, executive or "frontal lobe" function, attention, vi¬
suospatial function, and motor speed.11 Performance on each
Table 1. Subjects Stratified by Serostatus*
Mean (SD)
CD4
Duration of Lymphocyte Kurtzke
 Age, y Education, y Count, x109/L Scoref
HIV- 10 38.8(8.9) 17.4(2.7) 8.7(271) 0.8(0.8)
HIV+ 20 39.2(8.2) 16.0(2.7) 2.6 (274) 1.0(1.1)
* HIV indicates human immunodeficiency virus; minus sign, negative;
and plus sign, positive.
t Score according to a modified version of the Kurtzke Disability Status
Scale for Multiple Sclerosis.
  <. 01.
No HIV-positive subject had a focal neurological ex¬
amination. Four HIV-positive subjects had a psychiatric
diagnosis of depression, and one HIV-positive subject had
psychosis. Eight HIV-positive subjects had abnormal find¬
ings from their neuropsychological examinations. Seven
subjects met criteria for HIV-1-associated minor cogni-
rive or motor disorder, and one subject met criteria for
ADC stage 1.20 All HIV-negative subjects had normal find¬
ings from their psychiatric and neuropsychological ex¬
aminations.
There was no significant difference in the fre¬
quency of atrophy or the number of white-matter hyper¬
intensities on MRI scans between HIV-negative and
HIV-positive subjects. No opportunistic infections or neo¬
plasms were seen.
The interobserver reliability for all three raters for
SPECT scan classification was good, as indicated by a  
index of 0.46 (P<.01). Table 2 shows that SPECT scans
were abnormal in 15 (75%) of the 20 HIV-positive sub¬jects and in two (20%) of the 10 HIV-negative subjects.
Focal defects were seen in all cortical areas, as well as in
the basal ganglia, thalamus, and cerebellum in HIV-
positive subjects. No specific cortical or subcortical re¬
gion predominated. By restricting analysis to HIV-
positive subjects, abnormal SPECT scans were not seen
more frequently in subjects with a CD4 lymphocyte count
of less than 2X109/L than in subjects with a CD4 lym-
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test was compared with norms for age- and education-
matched populations and then rated as normal, border¬
line (at least 1 SD below the expected mean), or defective(at least 2 SDs below the expected mean). Cognitive im¬
pairment was defined as abnormal if there was a defective
performance on one test or a borderline performance on
two tests.
MRI SCANS
For all subjects, an MRI scan was performed within 1 year
of the SPECT study. Scans were performed on a 1.5-T sys¬
tem.16 The imaging protocol consisted of T2-weighted axial
and coronal scans (repetition and echo times, 3500 and 80
milliseconds, respectively), with a slice thickness of 5 mm
and a 4-mm separation between slices. Images were ac¬
quired in a 512X512 matrix. The MRI scans were evalu¬
ated by one neuroradiologist who had knowledge of each
subject's age but who was blind as to all other clinical data,
including serostatus. Atrophy, small areas of high-signal
intensity, and larger focal lesions were recorded. Atrophy
was rated as absent or mild (normal) or moderate or se¬
vere (abnormal). Small foci of high-signal intensity (S3 mm
and <2 cm), diffuse foci of high-signal intensity (ä2 cm),
and focal lesions that were consistent with opportunistic
infections, neoplasms, strokes, or arteriovenous malfor¬
mations were also noted.
SPECT SCANS
Image acquisition began 30 minutes after intravenous injec¬
tion of 20 mCi of technetium Tc 99m exametazime (Ceretec,
Amersham, Ltd, Amersham, England). Data were acquired
on a dedicated brain scanner (SME 810x, Strichman Medi¬
cal Equipment, Boston, Mass) by employing 2 to 3 million
counts per slice and by covering the complete cranial volume
at 6-mm axial slice spacing. An 800 collimator was used. Sys¬
tem resolution was 8-mm full-width half maximum. Trans¬
verse slices were reconstructed by two-dimensional decon-
volution with iterative attenuation correction,17 and coronal
and sagittal views were generated as required.
The SPECT scans were independently evaluated by three
readers (N.S., I.P., and R.L.V.H.) who were blind to the se¬
rostatus of the subjects, and a consensus diagnosis was then
obtained. Studies were evaluated by using a horizontal pro¬
file analysis to quantify the degree of asymmetry in radioac¬
tive tracer activity in a comparison of left with right sides. Re¬
sults ofstudies were defined as normal or abnormal based on
the presence and number of focal defects. A focal defect was
defined as a 20% or greater asymmetry in radioactive tracer
activity based on a side-to-side comparison in the axial plane.
A focal abnormality was considered to be significant when it
was confirmed on an adjacent axial slice and also in the coro¬
nal plane. Scans were rated as normal if no or one focal de¬
fect was seen. Scans were rated as abnormal if two or more
focal defects were seen.
STATISTICAL ANALYSIS
Neuropsychological, MRI, and SPECT data were collapsed
into two categories: normal or abnormal. The agreement be¬
tween readers with respect to SPECT scan classification was
evaluated by using the  statistic. The significance of group
differences for quantitative data (eg, age, education, and CD4
lymphocyte count in HIV-positive and HIV-negative subjects)
was assessed with t tests. For categorical data (eg, the Kurtzke
score), the Wilcoxon Rank Sum Test was performed. To com¬
pare proportions (eg, frequencies ofneuroimaging test abnor¬
malities), Fisher's Exact Test (two tailed) was used. Simple
odds ratios (ORs), OR adjusted for age and log In CD4 lym¬
phocyte count using logistic regression, and OR stratified by
cognitive impairment were calculated to assess the associa¬
tion of a positive serostatus and abnormal SPECT scans.18·19
The In CD4 lymphocyte count was used because the distri¬
bution of the CD4 count was skewed. In addition, logistic re¬
gression was used to assess the value of SPECT scans as pre¬
dictors ofpositive serostatus or abnormal neuropsychologi¬
cal testing results.
phocyte count of greater than 2X109/L. None of the four
HIV-positive subjects with depression had a decreased
uptake in the frontal lobes although three had focal de¬
fects in the right temporal lobe.
Compared with HIV-negative subjects, the odds of
having an abnormal SPECT scan were 12 times higher
for HIV-positive subjects (95% confidence interval [CI],
1.9 to 76.4). After adjusting for age and In CD4 lympho¬
cyte count using logistic regression, the OR remained sig¬
nificant (OR, 52; 95% CI, 3.3 to 807.5).
Eight (67%) of the 12 HIV-positive subjects with nor¬
mal neuropsychological test results had abnormal SPECT
scans. The Figure shows the transaxial plane images of
an HIV-positive subject with normal neuropsychological
testing results. Focal defects are noted in the right frontal
lobe, right part of the thalamus, and left part of the cer¬
ebellum. Logistic regression modeling for an abnormal
SPECT scan in HIV-positive subjects with normal neuro¬
psychological testing results, as compared with that in HIV-
negative subjects, revealed an OR of8 (95% CI, 1.1 to 56.8).
Seven (88%) of the eight HIV-positive subjects with
abnormal neuropsychological testing results had abnor¬
mal SPECT scans. Logistic regression modeling for an ab¬
normal SPECT scan in HIV-positive subjects with ab¬
normal neuropsychological testing results, as compared
with that in HIV-negative subjects, revealed an OR of 28(95% CI, 2.1 to 379.3). There was no significant differ¬
ence in the frequency of abnormal SPECT scans be¬
tween HIV-positive subjects with abnormal neuropsy¬
chological testing results and HIV-positive subjects with
normal neuropsychological testing results.
Because one subject met criteria for ADC (stage 1),
a subanalysis was performed by removing this subject from
the statistical analysis. In this subanalysis, as compared
with that in HIV-negative subjects, the OR for an abnor¬
mal SPECT scan in all HIV-positive subjects (OR, 11 ; 95%
CI, 1.8 to 71.6) and the OR for an abnormal SPECT scan
in HIV-positive subjects with abnormal neuropsycho¬
logical testing results (OR, 24; 95% CI, 1.7 to 330.8) re¬
mained significant.
Using logistic regression, an abnormal SPECT scan pre¬
dicted HIV-positive serostatus (P<.01). In addition, an ab-
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Table 2. Number of Normal and Abnormal SPECT
Scans and OR for Abnormal SPECT Scans
for Subjects Stratified by Serostatus*










1.0 (reference 1.0 (reference
value) value)
12(1.9-76.4)1* 52(3.3-807.5)1
* SPECT indicates single-photon emission computed tomography; OR,
odds ratio; CI, confidence interval; CD4, CD4 lymphocyte count; HIV,
human immunodeficiency virus; minus sign, negative; and plus sign,
positive.
tP<. 05.
Technetium Tc 99m exametazime single-photon emission computed
tomography axial images in a 37-year-old human immunodeficiency virus
type 1-positive gay man with normal neuropsychological testing results.
Focal defects are noted in the right (R) part of the thalamus (slice 4), right
frontal lobe (slice 11), right posterior frontal lobe (slice 8), and left (L)
medial part of the cerebelium (slice 1).
normal SPECT scan, after adjusting for age, predicted ab¬
normal neuropsychological testing results (P<.05).
COMMENT
Multifocal cortical and subcortical SPECT uptake de¬
fects can help to distinguish HIV infection from psychi¬
atric disorders, such as psychosis or depression.5 How¬
ever, this pattern cannot be distinguished from that seen
in long-term intravenous cocaine and heroin use.10 Tatsch
et al3 reported SPECT abnormalities in both early and ad¬
vanced stages of HIV infection. More than 50% of the pa¬
tients with abnormal SPECT findings had normal com¬
puted tomographic or MRI scans. However, the risk factor
for HIV disease was not defined, and no controls were
used as a comparison with the HIV-positive subjects with
early infection in this study.3 Other studies of SPECT in
early HIV infection have had a significant proportion of
parenteral drug users in their subject population.7"9 The
SPECT perfusion defects that were observed in long-
term intravenous cocaine and heroin users were, in part,
reversible with short-term (1- to 4-week) abstinence.21
The goal in this study was to determine if techne¬
tium Tc 99m exametazime SPECT could distinguish gay
HIV-positive subjects without cognitive impairment or
with mild cognitive impairment from gay HIV-negative
control subjects. No subject reported a significant his¬
tory of active parenteral drug use. The control subjects
who were used in this investigation were age matched
to the HIV-positive subjects and were in the same HIV-
risk group. The presence of SPECT focal defects in two
control subjects was unexpected. This may simply re¬
flect the sensitivity of the SPECT technique. However,
one of the seronegative control subjects with an abnor¬
mal SPECT scan seroconverted 6 months later. No other
seroconversions occurred among the seronegative sub¬
jects during 1 year of follow-up since the SPECT exami¬
nations were performed.
These results show that HIV-positive gay men with¬
out cognitive impairment were more likely to have an
abnormal SPECT scan than were HIV-negative gay men.
The HIV-positive gay men with mild cognitive impair¬
ment (minor cognitive/motor disorder), but not ADC,
were also more likely to have an abnormal SPECT scan
compared with HIV-negative gay men.
There are several limitations to this study. Bilateral
focal defects could be missed by side-to-side compari¬
sons for focal abnormalities. In addition, defect size, glo¬
bal reduction in cerebral uptake, and heterogeneous cor¬
tical uptake patterns were not considered in the
determination of SPECT scan abnormalities. Semiquan¬
titative analysis using cortical region-of-interest/
subcortical or cerebellar activity ratios (ie, isolating the
activity in a cortical region and comparing it with the ac¬
tivity in a subcortical or cerebellar region) could not be
performed because of the presence of focal defects within
the subcortical structures and cerebellum. Cerebellar hy¬
poperfusion has been noted in prior studies of SPECT
in HIV infection.22
The cause of the focal SPECT uptake defects in HIV-
positive subjects remains unclear. They may result from
direct neuronal damage by the HIV-1 virus4·23·24 or toxic
effects of enzymes or cytokines that are secreted by in¬
fected cells.25·26 Subcortical demyelination27·28 may lead
to a cortical perfusion defect via the mechanism of dias¬
chisis.29·30 The HIV-1 virus may directly cause vascular
inflammation and damage that reduce flow.28·31"33 Alter¬
natively, the focal defects may not represent true corti¬
cal brain defects but rather enlarged cortical sulci due to
focal atrophy. Johnson et al34 reported that 65% of the
focal uptake defects that were seen in ADC corre¬
sponded to cortical gyri, and 35% of the defects corre¬
sponded to cortical sulci when SPECT studies were coreg-
istered with MRI studies.
This study demonstrates that SPECT focal defects
may be seen in HIV-1-infected gay men without cog¬
nitive impairment and suggests that SPECT results
may be predictive of HIV serostatus and neuropsycho¬
logical performance in HIV-positive gay men. Single-
photon emission computed tomography may be a
valuable neuroimaging tool in the diagnostic evalua¬
tion of cognitive impairment in HIV-positive gay men,
and further longitudinal studies to evaluate the role of
SPECT in predicting prognosis and response to the
treatment of HIV-1-associated cognitive impairment
should be performed.
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